1. Scrip
  2. >>Business

Novo Nordisk Q4 Preview: Rybelsus’s Launch Key Focus

Analysts Expect Strong Q4 GLP-1 Volumes Offset By US Pricing Pressures

 
• By Sten Stovall

Ozempic's continued good growth and the ongoing roll out of oral Rybelsus should revitalize growth and expand Novo's reach in the diabetes market this year.

Novo Nordisk
Novo Nordisk is becoming increasingly reliant on the high-growth GLP-1 class • Source: Shutterstock

Novo Nordisk AS, which reports full-year results on Wednesday, 5 February, will have closed out 2019 with another solid quarter, backed by its GLP-1 franchise, including initial sales of novel oral antidiabetic Rybelsus which analysts expect to become a blockbuster, forecasters said.

That strong overall performance should allow the Danish group meet its financial guidance for 2019 and underpin forecasts for a similar growth outlook for 2020, albeit one with contrasting dynamics of strong GLP-1 sales and robust

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 
• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.